COFCO Biotechnology Co., Ltd.
000930.SZ · SHZ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | CN¥4,449 | CN¥4,427 | CN¥4,385 | CN¥4,929 |
| % Growth | 0.5% | 0.9% | -11% | – |
| Cost of Goods Sold | CN¥4,131 | CN¥4,127 | CN¥4,031 | CN¥4,909 |
| Gross Profit | CN¥318 | CN¥300 | CN¥354 | CN¥20 |
| % Margin | 7.1% | 6.8% | 8.1% | 0.4% |
| R&D Expenses | CN¥32 | CN¥47 | CN¥54 | CN¥22 |
| G&A Expenses | CN¥0 | CN¥138 | CN¥125 | CN¥186 |
| SG&A Expenses | CN¥174 | CN¥185 | CN¥171 | CN¥240 |
| Sales & Mktg Exp. | CN¥0 | CN¥47 | CN¥46 | CN¥54 |
| Other Operating Expenses | CN¥164 | -CN¥25 | CN¥83 | -CN¥220 |
| Operating Expenses | CN¥370 | CN¥207 | CN¥308 | CN¥42 |
| Operating Income | -CN¥52 | CN¥94 | CN¥46 | -CN¥22 |
| % Margin | -1.2% | 2.1% | 1.1% | -0.4% |
| Other Income/Exp. Net | CN¥39 | CN¥5 | CN¥12 | CN¥29 |
| Pre-Tax Income | -CN¥13 | CN¥98 | CN¥58 | CN¥7 |
| Tax Expense | CN¥14 | CN¥30 | CN¥16 | -CN¥17 |
| Net Income | -CN¥28 | CN¥67 | CN¥41 | CN¥16 |
| % Margin | -0.6% | 1.5% | 0.9% | 0.3% |
| EPS | -0.015 | 0.036 | 0.022 | 0.008 |
| % Growth | -142.1% | 64.7% | 159.5% | – |
| EPS Diluted | -0.015 | 0.036 | 0.022 | 0.008 |
| Weighted Avg Shares Out | 1,856 | 1,859 | 1,859 | 1,860 |
| Weighted Avg Shares Out Dil | 1,856 | 1,859 | 1,859 | 1,860 |
| Supplemental Information | – | – | – | – |
| Interest Income | CN¥12 | CN¥12 | CN¥33 | CN¥10 |
| Interest Expense | CN¥24 | CN¥27 | CN¥23 | CN¥22 |
| Depreciation & Amortization | CN¥0 | CN¥124 | CN¥120 | CN¥120 |
| EBITDA | CN¥11 | CN¥165 | CN¥230 | -CN¥168 |
| % Margin | 0.3% | 3.7% | 5.2% | -3.4% |